Filing Flows › Monte Rosa Therapeutics (GLUE) › Q2 2025
Monte Rosa Therapeutics (GLUE) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
Monte Rosa Therapeutics (GLUE) reported revenue of $23.2M for the second quarter 2025 (Q2 2025), +394% from a year earlier and -73% from the quarter before. Operating margin was -67.1%, net loss $12.3M (53.0% of revenue).
Monte Rosa Therapeutics, Q2 2025: revenue $23.2M (+394% year over year), operating margin -67.1%, net loss $12.3M, operating cash flow −$34.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $23.2M | -73% | +394% |
| Operating profit | −$15.6M | -135% | — |
| Net earnings | −$12.3M | -126% | — |
| Operating cash flow | −$34.7M | — | — |
What changed
Revenue was $23.2M in Q2 2025, up 394% year over year and down 73% from the previous quarter.
Operating costs exceeded revenue by $15.6M, an operating margin of -67.1%. Total costs grew 4% against revenue growth of 394%. The quarter ended with a net loss of $12.3M, after a profit of $46.9M the previous quarter. Non-operating items added $4.5M, -40% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$34.7M. Non-cash charges added back $2.7M of depreciation and amortization and $4.9M of share-based compensation. Working capital and other items used $30.1M. Capital expenditures of $1.7M exceeded it, leaving free cash flow of −$36.4M.
Questions
What was Monte Rosa Therapeutics' revenue in the second quarter 2025?
Monte Rosa Therapeutics (GLUE) reported revenue of $23.2M for the second quarter 2025 (Q2 2025), +394% from a year earlier and -73% from the quarter before.
Was Monte Rosa Therapeutics profitable in the second quarter 2025?
Operating loss was $15.6M (-67.1% of revenue) and net loss $12.3M.